Apimeds Pharmaceuticals US (APUS) Return on Capital Employed (2025)

Apimeds Pharmaceuticals US (APUS) posted Return on Capital Employed of 15.67% for Q4 2025, up 73.18% on a QoQ basis from 58.44% in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Return on Capital Employed (2025) Analysis & Trends

Apimeds Pharmaceuticals US's Return on Capital Employed history runs 1 years deep, the most recent figure standing at 15.67% for Q4 2025.

Quarterly Return on Capital Employed changed N/A year-over-year to 15.67% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 15.67% (changed N/A YoY) and the FY2025 annual result came in at 16.69%, down 17474.0% from the prior year.
Return on Capital Employed was 15.67% for Q4 2025 at Apimeds Pharmaceuticals US, up from 58.44% in the prior quarter.
Across five years, Return on Capital Employed topped out at 83.71% in Q1 2025 and bottomed at 78.44% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	8.52%
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	27.36%
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-1.50%
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	21.43%
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	0.46%
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	20.04%
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	5.24%
10	Apimeds Pharmaceuticals US	8.17 Mn	8.17 Mn	-	-15.67%

Download Data